IS5378A - Apríl-nýstárlegt prótín sem hefur áhrif á vöxt - Google Patents

Apríl-nýstárlegt prótín sem hefur áhrif á vöxt

Info

Publication number
IS5378A
IS5378A IS5378A IS5378A IS5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A
Authority
IS
Iceland
Prior art keywords
april
affects growth
innovative protein
innovative
protein
Prior art date
Application number
IS5378A
Other languages
English (en)
Inventor
Tschopp Jurg
Original Assignee
Apotech Research And Development Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Research And Development Ltd. filed Critical Apotech Research And Development Ltd.
Publication of IS5378A publication Critical patent/IS5378A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS5378A 1997-09-12 2000-02-18 Apríl-nýstárlegt prótín sem hefur áhrif á vöxt IS5378A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
IS5378A true IS5378A (is) 2000-02-18

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5378A IS5378A (is) 1997-09-12 2000-02-18 Apríl-nýstárlegt prótín sem hefur áhrif á vöxt

Country Status (20)

Country Link
US (3) US20030138884A1 (is)
EP (1) EP1027431A2 (is)
JP (1) JP2001515712A (is)
KR (1) KR100618492B1 (is)
CN (1) CN1195849C (is)
AU (1) AU759717B2 (is)
BR (1) BR9812634A (is)
CA (1) CA2303615A1 (is)
CZ (1) CZ294615B6 (is)
EA (1) EA005411B1 (is)
EE (1) EE200000147A (is)
HU (1) HUP0004611A3 (is)
IL (1) IL134537A0 (is)
IS (1) IS5378A (is)
NO (1) NO20001242L (is)
NZ (1) NZ503850A (is)
PL (1) PL339463A1 (is)
SK (1) SK3542000A3 (is)
TR (1) TR200000669T2 (is)
WO (1) WO1999012965A2 (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
JP2002516069A (ja) * 1997-09-30 2002-06-04 ファルマシア・アンド・アップジョン・カンパニー Ｔｎｆ関連死リガンド
AU1700999A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
NZ513284A (en) 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
MXPA02001665A (es) * 1999-08-17 2003-07-14 Biogen Inc Receptor de baff (bcma) como agente inmunorregulador.
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
EP1259544B1 (en) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
ATE329610T1 (de) * 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen
JP2003533218A (ja) 2000-05-12 2003-11-11 アムジエン・インコーポレーテツド Ａｐｒｉｌ／ｇ７０、ｂｃｍａ、ｂｌｙｓ／ａｇｐ−３及びｔａｃｉに関する物質の組成物及び使用方法
WO2001096528A2 (en) * 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
WO2002094192A2 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
EP2116259B1 (en) 2001-05-24 2012-01-25 ZymoGenetics, Inc. TACI-immunoglobulin fusion proteins
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003207464A1 (en) 2002-01-04 2003-07-24 Xencor Dominant negative proteins and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
EP1709072A1 (en) * 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
EP1836224A1 (en) 2004-12-23 2007-09-26 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
UA93516C2 (ru) 2005-08-09 2011-02-25 Займоджинетикс, Инк. Способы лечения b-клеточных злокачественных образований c помощью слитой молекулы taci-ig
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
JP5227174B2 (ja) * 2005-09-26 2013-07-03 アポテック コーポレーション リンパ腫患者の早期予後用のバイオマーカーとしてのａｐｒｉｌに対する抗体
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
NZ572373A (en) 2006-05-15 2012-02-24 Ares Trading Sa Methods for treating rheumatoid arthritis using a taci-ig fusion molecule
JP5867706B2 (ja) 2009-03-02 2016-02-24 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． 増殖誘導リガンド（ａｐｒｉｌ）に対する抗体
EP2542679A1 (en) * 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CN108441497B (zh) * 2013-09-23 2021-10-29 瑞泽恩制药公司 具有人源化信号调节蛋白基因的非人动物
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
AU2014353347B2 (en) * 2013-11-19 2020-07-02 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP4285923A3 (en) 2015-11-25 2024-03-06 Visterra, Inc. Antibody molecules to april and uses thereof
CA3199743A1 (en) 2020-10-29 2022-05-05 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
JP2024529128A (ja) 2021-08-11 2024-08-01 アクソ バイオファーマシューティカル， インコーポレイテッド ｓＢＣＭＡバリアント及びそのＦＣ融合タンパク質を使用するＩｇＡ、ＩｇＭ、及び／又はＩｇＧの産生を低減する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
ES2210354T3 (es) * 1996-03-14 2004-07-01 Human Genome Sciences, Inc. Factor de necrosis tumoral humano delta y epsilon.
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
EA200000310A1 (ru) 2000-10-30
WO1999012965A3 (en) 1999-06-03
HUP0004611A2 (hu) 2001-04-28
WO1999012965A2 (en) 1999-03-18
EE200000147A (et) 2001-02-15
KR20010023893A (ko) 2001-03-26
US20060084148A1 (en) 2006-04-20
CN1270632A (zh) 2000-10-18
NO20001242D0 (no) 2000-03-09
AU9316298A (en) 1999-03-29
KR100618492B1 (ko) 2006-08-31
JP2001515712A (ja) 2001-09-25
SK3542000A3 (en) 2000-08-14
US20030138884A1 (en) 2003-07-24
TR200000669T2 (tr) 2000-08-21
IL134537A0 (en) 2001-04-30
BR9812634A (pt) 2000-08-22
EA005411B1 (ru) 2005-02-24
CN1195849C (zh) 2005-04-06
NO20001242L (no) 2000-05-11
US20050112596A1 (en) 2005-05-26
CZ2000869A3 (cs) 2000-09-13
EP1027431A2 (en) 2000-08-16
NZ503850A (en) 2002-12-20
HUP0004611A3 (en) 2002-04-29
CA2303615A1 (en) 1999-03-18
CZ294615B6 (cs) 2005-02-16
AU759717B2 (en) 2003-04-17
PL339463A1 (en) 2000-12-18

Similar Documents

Publication Publication Date Title
IS5378A (is) Apríl-nýstárlegt prótín sem hefur áhrif á vöxt
DE69729021D1 (de) Flächiges Implantat
NO2010022I2 (no) Denosumab
DE69800491D1 (de) Baumschere
NO982097D0 (no) Peptider
DE69725567D1 (de) Haltetransplantat
NO982098D0 (no) Peptider
ITMI992109A0 (it) Innesto
HK1039158A1 (zh) Nlk1相互作用蛋白
ATE295417T1 (de) Angiostatin-bindendes protein
GB9816337D0 (en) Proteins
GB9828704D0 (en) Proteins
GB9828880D0 (en) Protein
DE59810662D1 (de) Koaxialverbinder
ID20403A (id) PEMBUATAN α-TOKOFEROL
DE69917203D1 (de) Wachse
GB9812607D0 (en) Protein
GB9809566D0 (en) Protein
GB9819038D0 (en) Protein
EP1127066A4 (en) MODIFIED PROTEINS
GB9816335D0 (en) Proteins
GB0320970D0 (en) Proteins
GB9816336D0 (en) Proteins
DK1088069T3 (da) Angiostatin-bindende protein
GB9823975D0 (en) Protein